Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients

This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer‐BioNTech) in 112 Allo‐HSCT patients. Antibody response to SARS‐CoV‐2 spike protein receptor‐binding domain was tested at the time of the second injection (Roche Elecsys). The study also...

Descripción completa

Detalles Bibliográficos
Autores principales: Chevallier, Patrice, Coste‐Burel, Marianne, Le Bourgeois, Amandine, Peterlin, Pierre, Garnier, Alice, Béné, Marie C., Imbert, Berthe‐Marie, Drumel, Thomas, Le Gouill, Steven, Moreau, Philippe, Mahe, Beatrice, Dubruille, Viviane, Blin, Nicolas, Lok, Anne, Touzeau, Cyrille, Gastinne, Thomas, Jullien, Maxime, Vanthygem, Sophie, Guillaume, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242867/
https://www.ncbi.nlm.nih.gov/pubmed/34226903
http://dx.doi.org/10.1002/jha2.242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242867/
https://www.ncbi.nlm.nih.gov/pubmed/34226903
http://dx.doi.org/10.1002/jha2.242

Ejemplares similares